Table 4 DXA at baseline and at 12 months
From: Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children
PATIENT | BMC(g/cm2) 0–12 m | LMB(g) 0–12 m | FAT(g) 0–12 m | FAT (%) 0–12 m | Z-SCORE 0–12 m | BMC-age related changes(%) 0–12 m |
|---|---|---|---|---|---|---|
1 | 0,798–0.949 | 26.778–29.9807 | 13.082–12.249 | 31–28 | -1.05 → -3.34 | 90.9–83.4 |
2 | 0,731–0,748 | 17.687–19.909 | 8071–10.922 | 30–34 | 2,08 → 4,31 | 116,9–135 |
3 | 0,759–0,832 | 20.751–23.293 | 9579–11.409 | 30–31 | 1,8 → 2,59 | 116,6–121,9 |
4 | 0,803–0,868 | 26.856–41.913 | 7014–5526 | 20-11 | -4,21 → -3,01 | 70,1–82,1 |
5 | 0,687–0,723 | 19.300–20.563 | 7181–7949 | 26–27 | 1,01 → 0,88 | 110,5–110,4 |
6 | 0,76–0,83 | 22.559–28.061 | 10.967–11.393 | 31-28 | -1,14 → -1,25 | 90–89,5 |
7 | NA-0,732 | NA-21.263 | NA-13.069 | NA-36 | NA → 1,56 | NA-112,8 |
P | 0,04 | 0,02 | 0,2 | 0,8 | 0,2 | 0,2 |